Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Polymorphism
Plasminogen activator inhibitor-1 (PAI-1) is a primary regulator of the fibrinolytic system in vivo and is an important inhibitor of the fibrinolytic system. PAI-1 is a glycoprotein that acts as an inhibitor of the fibrinolytic system by binding and inhibiting plasminogen activators such as tPA and UPA, thus forming inactive complexes which are then cleared by the liver. It is synthesized primarily by the liver and adipose tissue. PAI-1 is found as active and inactive forms. The active form is found in plasma, whereas the inactive form is found primarily in platelets, usually complexed with plasminogen activators.
Elevated levels of PAI-1 may suppress fibrinolysis leading to increased risk of thrombosis. A common single nucleotide polymorphism (4G/5G) at position −675 of the promoter region leads to differences in PAI-1 production. In vitro studies suggest the 4G allele results in greater fibrinolytic inhibition than the 5G allele because the 5G allele contains an additional binding site for a DNA-binding protein that can be a transcription repressor. Recent studies have shown that homozygosity or heterozygosity for the 4G PAI-1 allele is associated with increased thrombotic risk, myocardial infarction, pregnancy complications, and risk of meningococcal sepsis in children. In addition, PAI-1 may also be elevated in patients with metabolic syndrome, cancer, surgery, and pregnancy.
No association of the 5G allele with these conditions has been shown. Prevalence of 4G/4G, 4G/5G, and 5G/5G genotypes are 31.8%, 46.6%, and 21.6% respectively. This assay may be used as an aid in the diagnosis of venous thromboembolism and related thrombotic disorders. PAI-1 is an acute phase reactant and has a circadian rhythm.
Measurement of PAI-1 activity is done by a functional chromogenic test for the activity of this glycoprotein. The amount of the antigen is measured by an ELISA method. PAI-1 is an acute phase reactant and the amount of the antigen is elevated in conditions such as malignancy, hyperlipoproteinemia, sepsis, hypertriglyceridemia and third trimester pregnancy. Reference ranges for the antigen have been difficult to define since it is partially free in plasma and partially bound to t-PA.
- Evaluation of thrombotic risk
- Evaluation of deep venous thromboembolism, including women taking oral contraceptives or hormone replacement
- Evaluation of coronary artery disease and/or stroke
- Evaluation of recurrent miscarriages
- Evaluation of pregnancy complications
- Evaluation of meningococcal sepsis
Positive results are considered if homozygous (4G/4G) or heterozygous (4G/5G or 5G/4G) are detected. The presence of these variations could indicate increase risk in:
- Deep venous thrombosis
- Pulmonary embolism
- Patients with history of recurrent miscarriages
- Venous thrombosis
- Stroke
- Heart attack and stroke
- Preeclampsia
- Recurrent miscarriages
- Pregnancy complications and termination (spontaneous abortion)
- Cancer
Decreased in:
- Hyperfibrinolysis resulting from PAI-1 deficiency; this is a rare bleeding disorder
5G/5G genotypes
Whole Blood EDTA (Lavender), ACD (Yellow) or Heparin (Green).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: not supportive
- Thromb Haemost. 1995 Jul;74(1):71-6. [PMID: 8578529]
- Thromb Haemost. 1998 Dec;80(6):956-60. [PMID: 9869167]
- Br J Haematol. 2000 Oct;111(1):122-8. [PMID: 11091191]
- Clin Appl Thromb Hemost. 2003 Oct;9(4):299-307. [PMID: 14653439]
- Thromb Haemost. 1997 Apr;77(4):730-4. [PMID: 9134651]
- Thromb Res. 2008;122(6):736-42. [PMID: 17949795]